A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent.
ChEBI ID: 145947
| Member | Definition | Class |
|---|---|---|
| baicalin | The glycosyloxyflavone which is the 7-O-glucuronide of baicalein. It is an active ingredient of Chinese herbal medicine Scutellaria baicalensis. | baicalin |
| manumycin | A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. | manumycin A |
| ml 236a | A carbobicyclic compound that is ML-236C substituted by a hydroxy group at position 8S. It is a fungal metabolite isolated from Penicillium citrinum and exhibits anticholesteremic activity. | compactin diol lactone |
| pj-34 | A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | PJ34 |
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 13 (0.82) | 18.7374 |
| 1990's | 84 (5.31) | 18.2507 |
| 2000's | 372 (23.51) | 29.6817 |
| 2010's | 787 (49.75) | 24.3611 |
| 2020's | 326 (20.61) | 2.80 |
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 15 (0.93%) | 5.53% |
| Reviews | 60 (3.71%) | 6.00% |
| Case Studies | 1 (0.06%) | 4.05% |
| Observational | 1 (0.06%) | 0.25% |
| Other | 1,539 (95.24%) | 84.16% |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 1 | 1 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 13.4504 | 1 | 1 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 26.6795 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 13.4504 | 1 | 1 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 13.4504 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 13.4504 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 13.4504 | 1 | 1 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 0.8528 | 2 | 2 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 8.9125 | 1 | 1 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 2.2387 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | EC50 | 0.0200 | 1 | 1 |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | Kd | 0.1100 | 1 | 1 |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | Kd | 0.7000 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | EC50 | 10.2700 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Kd | 11.9500 | 2 | 2 |